Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 106-114

  Lefevre G ^a   Sedek G ^a   Jhee, S S ^b   Leibowitz, M T ^b   Huang, H L A ^a   Enz, A ^a   Maton, S ^c   Ereshefsky, L ^b   Pommier, F ^d   Schmidli, H ^a   Appel Dingemanse, S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CALIFORNIA CLINICAL TRIALS   (United States)

^c Novartis PharmOps   (United Kingdom)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; DRUG METABOLITE; NAP 22690; RIVASTIGMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; IC 50; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; VOMITING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ALZHEIMER DISEASE; BENZYLAMINES; BUTYRYLCHOLINESTERASE; CAPSULES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENOLS; PHENYLCARBAMATES; TREATMENT OUTCOME;

EID: 37548999377     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100242     Document Type: Article

References (15)

1. Lefèvre, G. et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J. Clin. Pharmacol. 47, 471-478 (2007).
2. Agid, Y., Dubois, B., Anand, R. & Gharabawi, G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr. Ther. Res. 59, 837-845 (1998).
3. Corey-Bloom, J., Anand, R. & Veach, J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 1, 55-65 (1998).
4. Jhee, S., Shiovitz, T., Hartman, R.D., Messina, J. & Anand, R. Centrally acting antiemetic mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clin. Neuropharmacol. 25, 122-123 (2002).
5. Inglis, F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. 127(Suppl 1): 45-63 (2002).
6. Darvesh, S. et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 17, 117-126 (2003).
7. Grossberg, G.T. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr. Ther. Res. 64, 216-235 (2003).
8. Jann, M.W., Shirley, K.L. & Small, G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41, 719-739 (2002).
9. Feldman, H. & Lane, R. Rivastigmine: a placebo-controlled trial of TID and BID regimens in patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry; published online 22 March 2007 http://jnnp.bmj.com/ cgi/rapidpdf/jnnp.2006.099424v1.
10. Hossain, M. et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin. Pharmacokinet. 41, 225-234 (2002).
11. Winblad, B. et al. A 6-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 22, 456-467 (2007).
12. Brimijoin, S. & Hammond, P. Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay. J. Neurochem. 51, 1227-1231 (1988).
13. Pommier, F. & Frigola, R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 784, 301-313 (2003).
14. Ellman, G.L., Courtney, K.D., Andres, V. & Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95 (1961).
15. Smith, B.P.; et al. Confidence interval criteria for assessment of dose proportionality. Pharm. Res. 17, 1278-1283 (2000).